Schedule of Warrants Activity (Details) - $ / shares |
6 Months Ended | 12 Months Ended |
|---|---|---|
Jun. 30, 2025 |
Dec. 31, 2024 |
|
| Warrants | ||
| Number of warrants, Balance | 2,291,276 | 1,162,792 |
| Weighted average price, Balance | $ 6.35 | $ 24.20 |
| Number of warrants, Issuance | 1,473,835 | 2,402,815 |
| Weighted average price, Issuance | $ 6.43 | $ 5.49 |
| Number of warrants, Expired | (6,250) | (357,742) |
| Weighted average price, Expired | $ 24.00 | $ 60.50 |
| Number of warrants, Exercise | (1,295,000) | (916,589) |
| Weighted average price, Exercise | $ 5.20 | $ (3.97) |
| Number of warrants, Balance | 2,463,861 | 2,291,276 |
| Weighted average price, Balance | $ 6.96 | $ 6.35 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price beginning. No definition available.
|
| X | ||||||||||
- Definition Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price ending. No definition available.
|
| X | ||||||||||
- Definition Weighted average price, exercise. No definition available.
|
| X | ||||||||||
- Definition Weighted average price, expired. No definition available.
|
| X | ||||||||||
- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants. No definition available.
|
| X | ||||||||||
- Definition Number of non-option equity instruments exercised by participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements for which rights to exercise lapsed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|